This project occurred at the Children’s Hospital of Eastern Ontario (CHEO), Canada, which specializes in pediatric care, with over 6,700 annual admissions, serving a population of 500,000 children and youth. CHEO patients with moderate to severe hemophilia A or B or von Willebrand disease (vWD) receiving prophylactic treatment with recombinant or plasma-derived clotting factor were eligible for a pharmacist assessment.